160 related articles for article (PubMed ID: 38363451)
1. Genomic Profiling Reveals Immune-Related Gene Differences in Lung Cancer Patients Stratified by PD1/PDL1 Expression: Implications for Immunotherapy Efficacy.
Ye Z; Huang T; Hu K; Zhou H; Huang L; Wang L
J Appl Genet; 2024 Feb; ():. PubMed ID: 38363451
[TBL] [Abstract][Full Text] [Related]
2. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors.
Wu Y; Lin L; Liu X
Dis Markers; 2020; 2020():7291586. PubMed ID: 32587640
[TBL] [Abstract][Full Text] [Related]
3. Analyses of multi-omics differences between patients with high and low PD1/PDL1 expression in lung squamous cell carcinoma.
Hu Z; Bi G; Sui Q; Bian Y; Du Y; Liang J; Li M; Zhan C; Lin Z; Wang Q
Int Immunopharmacol; 2020 Nov; 88():106910. PubMed ID: 32829091
[TBL] [Abstract][Full Text] [Related]
4. VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma.
Jlassi A; Rejaibi R; Manai M; Sahraoui G; Guerfali FZ; Charfi L; Mezlini A; Manai M; Mrad K; Doghri R
Front Oncol; 2024; 14():1352053. PubMed ID: 38634058
[TBL] [Abstract][Full Text] [Related]
5. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
Front Immunol; 2022; 13():862084. PubMed ID: 35493449
[TBL] [Abstract][Full Text] [Related]
6. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis.
Chang CH; Shih AC; Chang YH; Chen HY; Chao YT; Hsu YC
Front Oncol; 2021; 11():759497. PubMed ID: 34868974
[TBL] [Abstract][Full Text] [Related]
8. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
10. Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma.
Qi X; Qi C; Kang X; Hu Y; Han W
PeerJ; 2020; 8():e9362. PubMed ID: 32607285
[TBL] [Abstract][Full Text] [Related]
11. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
Wang YL; Gong Y; Lv Z; Li L; Yuan Y
J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
[No Abstract] [Full Text] [Related]
12. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Lei Q; Wang D; Sun K; Wang L; Zhang Y
Front Cell Dev Biol; 2020; 8():672. PubMed ID: 32793604
[TBL] [Abstract][Full Text] [Related]
13. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
14. Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy.
Luo K; Liu S; Shen X; Xu J; Shi C; Chao Y; Wen Z; Zhang K; Wang R; Liu B; Jiang Y
Front Cell Dev Biol; 2022; 10():1003656. PubMed ID: 36467413
[No Abstract] [Full Text] [Related]
15. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.
Paré L; Pascual T; Seguí E; Teixidó C; Gonzalez-Cao M; Galván P; Rodríguez A; González B; Cuatrecasas M; Pineda E; Torné A; Crespo G; Martin-Algarra S; Pérez-Ruiz E; Reig Ò; Viladot M; Font C; Adamo B; Vidal M; Gaba L; Muñoz M; Victoria I; Ruiz G; Viñolas N; Mellado B; Maurel J; Garcia-Corbacho J; Molina-Vila MÁ; Juan M; Llovet JM; Reguart N; Arance A; Prat A
Ann Oncol; 2018 Oct; 29(10):2121-2128. PubMed ID: 30165419
[TBL] [Abstract][Full Text] [Related]
16. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
Front Oncol; 2022; 12():804466. PubMed ID: 35280756
[TBL] [Abstract][Full Text] [Related]
17. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
Yang K; Xu J; Liu Q; Li J; Xi Y
Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
[TBL] [Abstract][Full Text] [Related]
18. High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1
Wang L; Xu X; Shang B; Sun J; Liang B; Wang X; You W; Jiang S
Int J Oncol; 2022 Apr; 60(4):. PubMed ID: 35211760
[TBL] [Abstract][Full Text] [Related]
19. Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction.
Patil SP; Fattakhova E; Hofer J; Oravic M; Bender A; Brearey J; Parker D; Radnoff M; Smith Z
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631439
[TBL] [Abstract][Full Text] [Related]
20. Liver FOXP3 and PD1/PDL1 Expression is Down-Regulated in Chronic HBV Hepatitis on Maintained Remission Related to the Degree of Inflammation.
Germanidis G; Argentou N; Hytiroglou P; Vassiliadis T; Patsiaoura K; Germenis AE; Speletas M
Front Immunol; 2013; 4():207. PubMed ID: 23898331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
